PharmaCyte Biotech annual ebitda
2012
2013
2023
2024
2025
2026
PharmaCyte Biotech EBITDA Growth & History (PMCB)
PharmaCyte Biotech's calculated EBITDA was −$5.3M for fiscal 2026.
View full PharmaCyte Biotech company overviewPharmaCyte Biotech annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-30 | −$5.3M | −$926,424 | — |
| 2025 | 2025-04-30 | −$4.4M | $2.1M | — |
| 2024 | 2024-04-30 | −$6.5M | −$64,514 | — |
| 2023 | 2023-04-30 | −$6.5M | — | — |
| 2013 | 2013-04-30 | −$1.7M | $240,162 | — |
| 2012 | 2012-04-30 | −$1.9M | — | — |
PharmaCyte Biotech quarterly ebitda
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q4 2026 | 2026-04-30 | −$961,828 | $80,036 | — |
| Q3 2026 | 2026-01-31 | −$2.1M | — | — |
| Q2 2026 | 2025-10-31 | −$1.4M | — | — |
| Q1 2026 | 2025-07-31 | −$848,305 | — | — |
| Q4 2025 | 2025-04-30 | −$1.0M | — | — |
| Q4 2013 | 2013-04-30 | −$455,939 | $26,123 | — |
| Q3 2013 | 2013-01-31 | −$340,840 | $61,670 | — |
| Q2 2013 | 2012-10-31 | −$348,796 | $47,078 | — |
| Q1 2013 | 2012-07-31 | −$538,786 | $105,291 | — |
| Q4 2012 | 2012-04-30 | −$482,062 | — | — |
| Q3 2012 | 2012-01-31 | −$402,510 | — | — |
| Q2 2012 | 2011-10-31 | −$395,874 | — | — |
| Q1 2012 | 2011-07-31 | −$644,077 | — | — |
PharmaCyte Biotech ebitda trends
Between the periods ended 2012-04-30 and 2026-04-30, PharmaCyte Biotech's ebitda decreased from −$1.9M to −$5.3M, a change of −$3.4M. The latest reported quarter, Q4 2026, shows −$961,828.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review PharmaCyte Biotech source filings ↗